Walethmade%25252525252525252525252525252525252525252525252525252525252525252525252525252525252520bromide

# Walethmade bromide (Glycopyrronium bromide) ## Overview Walethmade bromide is the generic name for **glycopyrronium bromide** (or glycopyrrolate). It is a synthetic quaternary ammonium antimuscarinic agent. Unlike atropine, it does not cross the blood-brain barrier readily, resulting in fewer CNS side effects. ## Primary Indications * Reduction of secretions (sialorrhea, intraoperative). * Reversal of neuromuscular blockade (off-label/adjunct). * Management of peptic ulcer disease (rarely used). * COPD/Asthma management (via inhalation, e.g., Seebri). ## Adult Dosing * **Pre-operative/Secretions:** 0.1–0.2 mg IM or IV administered 30–60 minutes prior to anesthesia. * **Neuromuscular blockade reversal:** 0.2 mg IV for every 1 mg of neostigmine. * **Chronic Sialorrhea:** 1 mg orally 3 times daily; titrate to response (max 2 mg TID). * **Inhalation (COPD):** 15.6 mcg inhaled once daily via specific delivery device. ## Pediatric Dosing * **Pre-operative/Secretions:** 0.004–0.01 mg/kg IV or IM (max 0.1 mg per dose). * **Chronic Sialorrhea (Weight-based):** Start 0.02 mg/kg orally 3 times daily; titrate by 0.02 mg/kg increments every 3–7 days. Max dose is often capped at 0.1 mg/kg/dose or 1.5–3 mg total daily depending on weight and local institutional protocols. ## Dose Adjustments * **Renal Impairment:** Reduce dose in severe renal impairment (CrCl <30 mL/min). Monitor closely for signs of toxicity (urinary retention, tachycardia). * **Hepatic Impairment:** No standard adjustment; use with caution. ## Contraindications * Hypersensitivity to glycopyrronium. * Closed-angle glaucoma. * Myasthenia gravis. * Obstructive uropathy (e.g., prostatic hypertrophy). * Paralytic ileus or severe ulcerative colitis/toxic megacolon. * Tachycardia secondary to cardiac insufficiency or thyrotoxicosis. ## Adverse Effects * **Anticholinergic effects:** Xerostomia (dry mouth), urinary retention, constipation, blurred vision, cycloplegia, and tachycardia. * **CNS:** Confusion or drowsiness (rare due to limited BBB penetration). * **Dermatologic:** Flushing and decreased sweating (risk of hyperthermia in heated environments). ## Key Drug Interactions * **Potentiation:** Increased effect with other anticholinergic drugs (e.g., antihistamines, TCAs, phenothiazines). * **Reduced Absorption:** May decrease absorption of concurrently administered oral medications due to delayed gastric emptying. * **Potassium Chloride:** Solid oral forms of KCl increase the risk of GI mucosal lesions when taken with anticholinergics. ## Monitoring * Heart rate (monitor for excessive tachycardia). * Presence of urinary retention. * Bowel function (risk of constipation/ileus). * Ocular assessment (if blurred vision occurs). ## Clinical Pearls * **Quaternary Structure:** Because it is a quaternary ammonium compound, it does not typically cause the CNS agitation or delirium often seen with atropine. * **Hydration:** Advise patients to maintain adequate fluid intake if tolerated, as xerostomia is the most common limiting side effect. * **Formulation:** Ensure the correct formulation is used; inhaled versions (COPD) are not interchangeable with oral or injectable systemic versions (sialorrhea/pre-op). * **Local Protocols:** Always verify dosing against local pediatric weight-based protocols or institutional formularies, as titration for sialorrhea varies significantly by practice environment. *** **Educational Disclaimer:** This information is for educational purposes only. Drug dosing, indications, and contraindications can change. Always verify current prescribing information using local formularies, official drug leaflets (e.g., FDA labels), or clinical decision support tools before prescribing or administering medication.